Zum Inhalt springen

Big Pharma’s race to stop Alzheimer’s before it starts

Swiss drugmaker Roche has launched a late-stage trial for trontinemab, a new Alzheimer's treatment designed to prevent symptoms by effectively crossing the blood-brain barrier. This initiative aims to overcome the limitations of current therapies and halt disease progression before cognitive decline begins.

Read the full article

in News
Gestalten Sie die Forschungsagenda für Advanced Practice Nursing in der Schweiz mit